However, the SUSTAIN six trial evaluated semaglutide, a GLP-1 analog, in patients with type 2 diabetes and high cardiovascular risk and discovered that semaglutide was associated with a higher incidence of diabetic retinopathy complications compared to placebo, with a hazard ratio (HR) of 1.76, particularly in patients with pre-existing DR ( This seemingly controversial impact of GLP-1RAs on DR may be because most trials focused on microvascular and cardiovascular outcomes rather than DR
Well discuss how it compares to other leading options later in this guide
By improving insulin sensitivity and producing significant weight loss, the medication addresses the underlying dysfunction driving prediabetes
In animal models, BPC-157 (Body Protection Compound-157), a pentadecapeptide derived from a protective protein found in gastric juice, has been shown to support tendon, ligament, and muscle recovery, protect the gastrointe
There are reports that counterfeit GLP-1 drugs from India, Turkey, China, and other foreign sources have infiltrated the U.S
3 These are different effector systems with different adaptive properties